Hairy cell leukemia: an update
GR Goodman, KJ Bethel, A Saven - Current opinion in hematology, 2003 - journals.lww.com
GR Goodman, KJ Bethel, A Saven
Current opinion in hematology, 2003•journals.lww.comHairy cell leukemia is an indolent, chronic B-cell lymphoproliferative disorder comprising
approximately 2 to 3% of all adult leukemias in the United States. Hairy cells are clonal
expansions of mature, activated B-cells. They co-express CD11c, CD19, CD20, CD22,
CD25, and CD103. Hairy cells possess clonal immunoglobulin gene rearrangements and
express monoclonal surface immunoglobulin of either IgG or multiple heavy-chain isotypes.
Treatment of hairy cell leukemia should be considered for symptomatic patients. It is …
approximately 2 to 3% of all adult leukemias in the United States. Hairy cells are clonal
expansions of mature, activated B-cells. They co-express CD11c, CD19, CD20, CD22,
CD25, and CD103. Hairy cells possess clonal immunoglobulin gene rearrangements and
express monoclonal surface immunoglobulin of either IgG or multiple heavy-chain isotypes.
Treatment of hairy cell leukemia should be considered for symptomatic patients. It is …
Abstract
Hairy cell leukemia is an indolent, chronic B-cell lymphoproliferative disorder comprising approximately 2 to 3% of all adult leukemias in the United States. Hairy cells are clonal expansions of mature, activated B-cells. They co-express CD11c, CD19, CD20, CD22, CD25, and CD103. Hairy cells possess clonal immunoglobulin gene rearrangements and express monoclonal surface immunoglobulin of either IgG or multiple heavy-chain isotypes. Treatment of hairy cell leukemia should be considered for symptomatic patients. It is indicated in patients with significant neutropenia, anemia, thrombocytopenia, symptomatic splenomegaly, constitutional symptoms due to hairy cell leukemia, or recurrent serious infections. Many treatments exist, including cladribine, pentostatin, interferon-alpha, splenectomy, rituximab (mabthera), and BL-22 immunotoxin.
Lippincott Williams & Wilkins